Jul 2026· Cell Death and Differentiation· 0 citations· 42 references
Medicine
TL;DR
It is established that the lncRNA MNX1-AS1 acts as a crucial driver of one-carbon metabolism reprogramming in non-small cell lung cancer and highlighted that the newly identified MNX1-AS1/CACYBP/β-catenin axis may serve as a potential prognostic biomarker and therapeutic target for lung cancer intervention.
Abstract
Lung cancer remains the leading cause of cancer-related death worldwide, and long noncoding RNAs (lncRNAs) have been implicated in its tumourigenesis and progression. However, the roles lncRNAs play in lung cancer remain unclear. In this study, we discovered an important role for the lncRNA MNX1 Antisense RNA 1 (MNX1-AS1) as a critical regulator of one-carbon metabolism reprogramming. Glutamine depletion altered chromatin accessibility, leading to downregulation of MNX1-AS1, while elevated expression of MNX1-AS1 was correlated with poor prognosis in patients with non-small cell lung cancer. Functional studies showed that MNX1-AS1 promoted cell proliferation and sphere formation in vitro, and subcutaneous and orthotopic tumour growth in vivo. Mechanistically, MNX1-AS1 directly binds to calcyclin binding protein (CACYBP), protecting it from ubiquitin-mediated degradation; thus, the MNX1-AS1/CACYBP complex accelerates the transcription of key one-carbon metabolism-related genes through the Wnt/β-catenin pathway. MNX1-AS1/CACYBP/β-catenin axis upregulated key one-carbon metabolism-related genes, which were essential for generating related metabolites and maintaining cellular redox balance to support lung cancer cell proliferation. These findings established that the lncRNA MNX1-AS1 acts as a crucial driver of one-carbon metabolism reprogramming in non-small cell lung cancer and highlight that the newly identified MNX1-AS1/CACYBP/β-catenin axis may serve as a potential prognostic biomarker and therapeutic target for lung cancer intervention.
It is suggested that UPK1A-AS1 is a hypoxia‐inducible oncogenic lncRNA that plays dual roles in cancer, with cancer type‐dependent associations with progression and immune modulation across malignancies and mechanistically mediating hypoxia‐associated drug resistance in HCC.
Ze-Kai Li, Min Luo, Shu-Sen Fang et al.· Analytical Cellular Patholog...· 0 citations
GAS6-AS1 represents a promising molecule for understanding cancer pathogenesis and developing novel strategies for precision cancer diagnosis and treatment, although further clinical validation and mechanistic studies are still required.
Zhi-Ling Lu, Wen-Bing Huang, Jin-Tao He et al.· Biomedical Reports· 0 citations
Investigating the regulatory mechanism of the long non-coding RNA deoxyguanosine kinase antisense RNA 1 in LUAD reveals an m6A-dependent mechanism governing DGUOK-AS1 stability and provides insights into its contribution to LUAD progression.
Menghao Yang, Jia-En Wu, Youjie Li et al.· iScience· 0 citations
This study uncovers a therapeutic vulnerable lncRNA-centric circuitry and provides compelling preclinical evidence for the development and application of a novel RNA targeting-LNP based therapy for treatment of myeloid leukemia.
Zhenggen Jin, Brendan D. Ma, Karen Y. T. Chan et al.· bioRxiv· 0 citations
A mechanism wherein SChLAP1 modulates AR signaling to promote PCa growth and progression is suggested, suggesting its molecular mechanism and potential to be used as a therapeutic target or biomarker.
The findings suggest that LINC01252 functions as a SAM-dependent, m 7 G-related lncRNA, acting as a transcriptional repressor of NUPR1 and WDR4, while establishing a negative feedback loop between LINC01252 and WDR4.
Xue-Han Zhao, Min Shi, Li Zhao et al.· Cell Death & Disease· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.